The immunotherapy developer, which counts Eli Lilly, Pfizer, Taiho and Ping An as investors, floated in the middle of its range after raising $160m in venture funding.
NextCure, a US-based immuno-oncology drug developer backed by pharmaceutical companies Taiho, Pfizer and Eli Lilly and insurance group Ping An, has secured $75m in its initial public offering.
The offering consisted of 5 million shares on the Nasdaq Global Select Market priced at $15 each, in the middle of its $14 to $16 range.
NextCure is working on immunomedicines that will treat diseases related to the human immune system such as cancer, by restoring normal immune system functioning.
The company…
